Tolerability Matters: The drug's apparent manageable side effect profile is as crucial as its efficacy for long-term patient success
Tirzepatide has been shown in clinical trials to reduce the risk of cardiovascular events at various doses, suggesting a potential treatment option for patients who are obese or overweight [2]
Many commercial plans may cover GLP-1 medications for obesity or metabolic conditions
For optimal results, maintain a balanced diet and healthy lifestyle
The Pat McAfee Show , according to a post on X
The composite 'all non-GLP-1 RA' group included insulin, metformin, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, sulfonylureas, meglitinides, thiazolidinediones, and alpha-glucosidase inhibitors